TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26254812
Drug: HIT'91 maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIT'91 maintenance strategy (postoperative craniospinal radiotherapy, and maintenance chemotherapy)
Study: 26259955
Drug: Trametinib (1.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (1.0, 2.0, or 3.0 mg once daily)
Study: 26259955
Drug: Trametinib (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (2.0 mg once daily) in combination with gemcitabine (1000 mg/m(2))
Study: 26259955
Drug: Trametinib monotherapy
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib monotherapy
Study: 26261238
Drug: ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ropeginterferon alfa-2b (50 to 540 µg, administered every 2 weeks)
Study: 26261849
Drug: Docetaxel in
Normalized name: docetaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel in combination with nintedanib
Study: 26263403
Drug: ETR 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETR 400 mg plus TDF/FTC 300/200 mg once daily
Study: 26264378
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg daily for 4 weeks of a 6-week cycle (Cohort A)
Study: 26264378
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg daily on a continuous basis (Cohort B)
Study: 26265463
Drug: Non-nucleotide reverse
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleotide reverse transcriptase inhibitor- and integrase-strand inhibitor-based cART
Study: 26265479
Drug: PUR118 5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR118 5.5 mg
Study: 26265479
Drug: PUR118 11.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR118 11.0 mg
Study: 26265479
Drug: PUR118 2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR118 2.8 mg
Study: 26265479
Drug: PUR118 high
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUR118 high dose (11.0 mg)
Study: 26268514
Drug: Carnitine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnitine (20 mg/kg, IV) prior to IVIR
Study: 26268514
Drug: IVIR (Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIR (Sodium ferric gluconate, [125 mg/100 ml] for 8 weeks)
Study: 26268782
Drug: 60-min rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60-min rituximab infusion
Study: 26268782
Drug: Standard second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard second dose infusion recommendation
Study: 26269365
Drug: Sugar-sweetened beverage
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-sweetened beverage consumption (dose-response analysis)
Study: 26271944
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg once daily) with nevirapine (400 mg once daily) and abacavir/lamivudine (600/300 mg once daily)
Study: 26281907
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg/day for 21 days
Study: 26282537
Drug: Clinical treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical treatment offered to all infected participants.
Study: 26282634
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of methotrexate and cytarabine followed by R-HDS (cyclophosphamide, cytarabine, and etoposide) supported by autologous stem-cell transplantation (ASCT). Treatment included eight doses of rituximab and four doses of intrathecal liposomal cytarabine.
Study: 26283670
Drug: Azithromycin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1.5 g for 5 days)
Study: 26283670
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g single oral dose)
Study: 26284823
Drug: Lenalidomide 15
Normalized name: lenalidomide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 15 mg/day for 21/28 days
Study: 26284932
Drug: Methylphenidate (osmotic-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (osmotic-release oral system)
Study: 26285768
Drug: Tamoxifen (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (120 mg PO twice daily) and bortezomib (1.3 mg/m2 IV on specified days) per 6-week cycles
Study: 26288246
Drug: Open-label venlafaxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label venlafaxine XR (titrated up to 300 mg/d) for 12 weeks
Study: 26288277
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) via single colonoscopic administration
Study: 26291296
Drug: Anti-TNF-α agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-α agents in patients with AS
Study: 26292221
Drug: Pomalidomide 2
Normalized name: pomalidomide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 2 mg (Cohort 1)
Study: 26292221
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg (Cohort 2)
Study: 26293470
Drug: Automated electronic
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated electronic reminders for earlier switching from i.v. to p.o. antibiotics
Study: 26293568
Drug: SmartCare services
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SmartCare services with remote monitoring and health care services in addition to existing treatment.
Study: 26293568
Drug: Existing outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing outpatient treatments (control group).
Study: 26293568
Drug: Existing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing treatment (control group).
Study: 26296092
Drug: CC-486 (300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (300mg once-daily for 14 or 21 days per 28-day cycle)
Study: 26296092
Drug: CC-486 (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (200mg twice-daily for 14 or 21 days per 28-day cycle)
Study: 26296092
Drug: CC-486 (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (200mg twice-daily for 21 days per 28-day cycle)
Study: 26296092
Drug: CC-486 (300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (300mg once-daily for 21 days per 28-day cycle)
Study: 26296092
Drug: CC-486 (extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (extended dosing)
Study: 26296295
Drug: Afatinib 40mg
Normalized name: AFATINIB 40MG TAB
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib 40mg once daily combined with paclitaxel 80mg/m(2) (days 1, 8 and 15 every four weeks)
Study: 26296295
Drug: Afatinib 50mg
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib 50mg once daily combined with paclitaxel 80mg/m(2) (days 1, 8 and 15 every four weeks)
Study: 26296295
Drug: Afatinib and
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib and paclitaxel combination
Study: 26296371
Drug: Irreversible electroporation
Normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irreversible electroporation (IRE) treatment of the prostate
Study: 26296952
Drug: RRx-001 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRx-001 (10 mg/m(2), 16·7 mg/m(2), 24·6 mg/m(2), 33 mg/m(2), 55 mg/m(2), 83 mg/m(2))
Study: 26296952
Drug: RRx-001 (16·7
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRx-001 (16·7 mg/m(2))
Study: 26299414
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care with prescribed medications or other therapies
Study: 26300782
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day XOS for 8 weeks
Study: 26300919
Drug: Amoxicillin/Clavulanic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/Clavulanic Acid (875 mg/125 mg BID, n = 235)
Study: 26300919
Drug: Clindamycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (150 mg QID, n = 237)
Study: 26300919
Drug: Amoxicillin/Clavulanic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/Clavulanic Acid
Study: 26300919
Drug: Amoxicillin/Clavulanic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/Clavulanic Acid and Clindamycin
Study: 26300986
Drug: Pentoxifylline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1200 mg daily, n=87)
Study: 26301100
Drug: Edratide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edratide 0.5 mg
Study: 26301100
Drug: Edratide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edratide 1.0 mg
Study: 26301100
Drug: Edratide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edratide 2.5 mg
Study: 26301100
Drug: Edratide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edratide (all doses)
Study: 26304481
Drug: Dual intramuscular
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual intramuscular and intra-arterial injection of bone marrow mononuclear cells harvested from the iliac crest
Study: 26304866
Drug: Dabigatran treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran treatment initiated within 24 hours of minor stroke, continued for 30 days.
Study: 26304872
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg once per day for 4 weeks on and 2 weeks off plus intravenous trebananib 10 mg/kg once per week (cohort A)
Study: 26304872
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg once per day for 4 weeks on and 2 weeks off plus intravenous trebananib 15 mg/kg once per week (cohort B)
Study: 26305021
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of levobupivacaine 0.5 % (2 ml/h for 48 hours)
Study: 26305021
Drug: Saline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (2 ml/h for 48 hours)
Study: 26306290
Drug: Desmopressin (dDAVP)
Normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (dDAVP) administered by intravenous infusion in saline, 30-60 min before and 24 h after surgical resection.
Study: 26308285
Drug: Tumor-infiltrating lymphocytes
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor-infiltrating lymphocytes (TILs) therapy
Study: 26308942
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring of gemcitabine
Study: 26310540
Drug: Latent iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latent iron deficiency (serum ferritin ≤75 ng/mL)
Study: 26310540
Drug: Normal iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal iron status (serum ferritin >75 ng/mL)
Study: 26310596
Drug: Control for
Normalized name: Anti Acne Control Formula Top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control for alternative sex-linked explanations (i.e., depression and drug use)
Study: 26310837
Drug: CC rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CC rate 100-120/min and CC depth ≥ 60 mm (without mattress deflection correction)
Study: 26310837
Drug: CC depth
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC depth
Study: 26310837
Drug: Deeper CC
Normalized name: Titanium Dioxide 0.38 g in 4.25 g TOPICAL POWDER [Purminerals 4 in 1 Makeup SPF 15 Deeper]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deeper CC
Study: 26310975
Drug: RG7256 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7256 (200 mg QD to 2400 mg BID)
Study: 26310975
Drug: RG7256 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7256 (high dose levels >1200 mg BID)
Study: 26312070
Drug: Vildagliptin added-on
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin added-on to metformin
Study: 26312070
Drug: Glibenclamide added-on
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide added-on to metformin
Study: 26312852
Drug: Valaciclovir (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir (8 g daily) for 6 months
Study: 26312852
Drug: Valaciclovir (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir (8 g daily)
Study: 26313445
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (DCV) 60 mg once daily plus PEG-IFN 180 µg weekly and RBV 1,000-1,200 mg/day (weight-based) twice daily
Study: 26314624
Drug: 17D-204 yellow
Normalized name: Flavivirus yellow fever virus 17D-204 whole
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17D-204 yellow fever vaccine (Stamaril, Sanofi-Pasteur, Lyon, France), 8 vials of lyophilized vaccine, viral quantification, cloning and sequencing of C/prM/E region.
Study: 26314729
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose challenge
Study: 26314729
Drug: Oral lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lipid challenge
Study: 26314740
Drug: Standardized measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized measurement of CRP levels with enhanced CT-scan if CRP exceeds 140 mg/L on postoperative day 3, 4, or 5.
Study: 26314822
Drug: Icatibant injection
Normalized name: Icatibant Injection
DrugBank: Icatibant (DB06196)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Icatibant injection
Study: 26314822
Drug: Icatibant injection
Normalized name: Icatibant Injection
DrugBank: Icatibant (DB06196)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Icatibant injection (2 or 3 injections)
Study: 26315712
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) primary prophylaxis (PP) planned in patients with FN risk at or above 20% threshold.
Study: 26315743
Drug: Ultrasound-facilitated, catheter-directed,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis using 24 mg of tissue-plasminogen activator (t-PA) administered as 1 mg/h for 24 h with a unilateral catheter or 1 mg/h/catheter for 12 h with bilateral catheters.
Study: 26315967
Drug: Continuing TKI
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing TKI therapy after RECIST progression
Study: 26315967
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of TKI therapy after RECIST progression
Study: 26316385
Drug: 10 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg/day liposomal amphotericin B (L-AMB) monotherapy for 1 month
Study: 26317543
Drug: MTKI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTKI treatment
Study: 26318254
Drug: Verproside combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verproside combined with IKK inhibitor (BAY11-7082)
Study: 26318254
Drug: Verproside combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verproside combined with TAK1 inhibitor (5z-7-oxozeaenol)
Study: 26321472
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of FdCyd and THU
Study: 26321472
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) administration of FdCyd after THU
Study: 26321472
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of THU with FdCyd
Study: 26324363
Drug: JNJ-42756493 10
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 10 mg administered on a 7-days-on/7-days-off schedule
Study: 26324363
Drug: JNJ-42756493 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 (various doses from 0.5 to 12 mg)
Study: 26324363
Drug: JNJ-42756493 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 (various doses)
Study: 26324363
Drug: JNJ-42756493 12
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 12 mg daily
Study: 26324363
Drug: JNJ-42756493 9
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 9 mg daily
Study: 26324363
Drug: JNJ-42756493 10
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 10 mg on a 7-days-on/7-days-off schedule
Study: 26324363
Drug: JNJ-42756493 (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-42756493 (starting at 4 mg daily)
Study: 26325106
Drug: Pimonidazole (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimonidazole (administered intravenously 16-20 hours before surgery)
Study: 26327481
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose to the thyroid (up to 0.2 Gy)
Study: 26327481
Drug: High radiation
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High radiation doses (>5 Gy) to pituitary gland
Study: 26327481
Drug: Nitrosourea chemotherapy
Normalized name: Bischloroethyl nitrosourea
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrosourea chemotherapy
Study: 26327481
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose to the thyroid
Study: 26327694
Drug: Carfilzomib (20S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (20S proteasome inhibitor)
Study: 26330458
Drug: BQ788 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ788 (3 mg, single intralesional application)
Study: 26330458
Drug: BQ788 (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ788 (cumulative dosage of 8 mg)
Study: 26330458
Drug: BQ788 (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ788 (cumulative dosage of 10 mg)
Study: 26331432
Drug: Bendamustine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 75 mg/m² on days 1 and 2, lenalidomide 25 mg on days 1-21, dexamethasone 40 mg on days 1, 8, 15, and 22
Study: 26331768
Drug: elosulfase alfa
Normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: elosulfase alfa 2.0 mg/kg/week for 52 weeks
Study: 26332545
Drug: Imetelstat (9.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat (9.4 mg/kg body weight, intravenous infusion every 1 to 3 weeks)
Study: 26332546
Drug: Imetelstat (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat (7.5 or 9.4 mg/kg intravenously once a week)
Study: 26333343
Drug: sNGAL ≥179
Approvals — FDA: no, EMA: no, PMDA: no
Description: sNGAL ≥179 ng/mL at 6 hours
Study: 26333343
Drug: sNGAL <179
Approvals — FDA: no, EMA: no, PMDA: no
Description: sNGAL <179 ng/mL and sCr <0.3 mg/dL
Study: 26333343
Drug: sNGAL ≥179
Approvals — FDA: no, EMA: no, PMDA: no
Description: sNGAL ≥179 ng/mL
Study: 26333343
Drug: sCr ≥0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCr ≥0.3 mg/dL
Study: 26333343
Drug: sNGAL <179
Approvals — FDA: no, EMA: no, PMDA: no
Description: sNGAL <179 ng/mL and sCr increase <0.3 mg/dL
Study: 26333343
Drug: sNGAL ≥179
Approvals — FDA: no, EMA: no, PMDA: no
Description: sNGAL ≥179 ng/mL and sCr increase <0.3 mg/dL
Study: 26333343
Drug: sCr increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCr increase ≥0.3 mg/dL
Study: 26333343
Drug: Urine NGAL
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine NGAL <20 ng/mL and sNGAL <179 ng/mL at 6 hours
Study: 26333941
Drug: Long-term Antiretroviral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term Antiretroviral Therapy (ART)
Study: 26334219
Drug: VS-6063 (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS-6063 (425 mg b.i.d.)
Study: 26334219
Drug: VS-6063 (300-425
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS-6063 (300-425 mg b.i.d.)
Study: 26334219
Drug: VS-6063 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS-6063 (various doses)
Study: 26334219
Drug: VS-6063 (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: VS-6063 (500-750 mg b.i.d.)
Study: 26334878
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with 8.5 g/day of RS type 2 for 4 weeks
Study: 26335961
Drug: RSV entry
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV entry inhibitor GS-5806
Study: 26336510
Drug: A-Part Gel(®)
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-Part Gel(®) as an anti-adhesive barrier
Study: 26336510
Drug: A-Part Gel(®)
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-Part Gel(®)
Study: 26336609
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin (glargine, starting dose 0.1 U/kg/day)
Study: 26336609
Drug: Oral antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidiabetic drug (OAD) therapy
Study: 26337145
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg subcutaneous injections at 4-week intervals
Study: 26337806
Drug: Ixazomib (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib (4.0 mg) plus lenalidomide (25 mg) and dexamethasone (40 mg)
Study: 26338094
Drug: Patisiran 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran 0.3 mg/kg every 4 weeks (Q4W)
Study: 26338094
Drug: Patisiran 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran 0.3 mg/kg Q3W